nCounter® PanCancer
Immune Profiling Panel
Helping Your Research
Perform multiplex gene expression analysis in human or mouse with 770 genes from different immune cell types, common checkpoint inhibitors, CT antigens, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinical actionable gene expression profiles in the context of cancer immunotherapy.
- Comprehensive profiling of the immune response optimized for immuno-oncology research
- Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
- Assess mechanistic pathway activity for single or combination studies
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- Multi-analyte analysis with Vantage 3D™ Assays
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Publications
Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer.
Neuronal nerve processes in the tumor microenvironment were highlighted recently. However, the origin of intra-tumoral nerves remains poorly known, in part because of technical difficulties in tracing nerve fibers via conventional histological preparations.
Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
Purpose: Cancer-associated fibroblasts (CAF) have been implicated as potential mediators of checkpoint immunotherapy response. However, the extensive heterogeneity of these cells has precluded rigorous understanding of their immunoregulatory role in the tumor microenvironment.
Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy.
Background: Genetically engineered T-cell immunotherapies for adoptive cell transfer (ACT) have emerged as a promising form of cancer treatment, but many of these patients develop recurrent disease. Furthermore, delineating mechanisms of resistance may be challenging since the analysis of bulk tumor profiling can be complicated by spatial heterogeneity.
Contact Us
Have questions or simply want to learn more?
Contact our helpful experts and we’ll be in touch soon.